New Research Partnership With Horizon Therapeutics Could Be The Next Revenue Catalyst For Xeris
Discusses the partnership and the potential income it might generate with some highlights from the recent Q3 result Technology-based biopharma company Xeris (NASDAQ:XERS) is set to boost its revenue with an upfront cash payment from a research collaboration and option agreement that was secured with mid-cap pharma Horizon Therapeutics (NASDAQ:HZNP). Xeris opened 12.6% higher at $1.43 on the news before traders banked profits, with the stock drifting lower and closing with a 3.9% gain at $1.32 on Wednesday afternoon. Q3 2022 hedge fund letters, conferences and more Find A Qualified Financial Ad...